Citadel Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $638K | Buy |
67,900
+11,400
| +20% | +$96K | ﹤0.01% | 8704 |
|
|
2025
Q4 | $460K | Buy |
56,500
+32,400
| +134% | +$400K | ﹤0.01% | 9229 |
|
|
2025
Q3 | $305K | Buy |
24,100
+7,800
| +48% | +$74.2K | ﹤0.01% | 10334 |
|
|
2025
Q2 | $112K | Buy |
16,300
+9,100
| +126% | +$66.1K | ﹤0.01% | 11241 |
|
|
2025
Q1 | $38.2K | Sell |
7,200
-34,500
| -83% | -$305K | ﹤0.01% | 12586 |
|
|
2024
Q4 | $492K | Sell |
41,700
-24,600
| -37% | -$413K | ﹤0.01% | 8582 |
|
|
2024
Q3 | $1.37M | Buy |
66,300
+62,400
| +1,600% | +$3.19M | ﹤0.01% | 6234 |
|
|
2024
Q2 | $176K | Sell |
3,900
-4,500
| -54% | -$189K | ﹤0.01% | 10109 |
|
|
2024
Q1 | $330K | Buy |
+8,400
| New | +$207K | ﹤0.01% | 9251 |
|
|
2023
Q1 | – | Sell |
-3,123
| Closed | -$10.4K | – | 14811 |
|
|
2022
Q4 | $10.4K | Sell |
3,123
-1,687
| -35% | -$6.49K | ﹤0.01% | 13624 |
|
|
2022
Q3 | $24K | Buy |
4,810
+180
| +4% | +$1.27K | ﹤0.01% | 11998 |
|
|
2022
Q2 | $35K | Buy |
4,630
+543
| +13% | +$5.25K | ﹤0.01% | 12139 |
|
|
2022
Q1 | $65K | Sell |
4,087
-2,290
| -36% | -$30.3K | ﹤0.01% | 12620 |
|
|
2021
Q4 | $118K | Sell |
6,377
-1,686
| -21% | -$45.7K | ﹤0.01% | 12542 |
|
|
2021
Q3 | $247K | Sell |
8,063
-2,150
| -21% | -$84.8K | ﹤0.01% | 11502 |
|
|
2021
Q2 | $561K | Sell |
10,213
-494
| -5% | -$27.4K | ﹤0.01% | 9804 |
|
|
2021
Q1 | $633K | Buy |
10,707
+5,480
| +105% | +$360K | ﹤0.01% | 9167 |
|
|
2020
Q4 | $196K | Sell |
5,227
-10,846
| -67% | -$405K | ﹤0.01% | 9745 |
|
|
2020
Q3 | $868K | Sell |
16,073
-334
| -2% | -$60.5K | ﹤0.01% | 6283 |
|
|
2020
Q2 | $4.13M | Buy |
16,407
+15,037
| +1,098% | +$3.04M | ﹤0.01% | 3360 |
|
|
2020
Q1 | $215K | Buy |
1,370
+530
| +63% | +$89.6K | ﹤0.01% | 7893 |
|
|
2019
Q4 | $138K | Sell |
840
-777
| -48% | -$115K | ﹤0.01% | 8405 |
|
|
2019
Q3 | $236K | Sell |
1,617
-673
| -29% | -$117K | ﹤0.01% | 7927 |
|
|
2019
Q2 | $476K | Buy |
2,290
+913
| +66% | +$195K | ﹤0.01% | 6891 |
|
|
2019
Q1 | $287K | Buy |
+1,377
| New | +$304K | ﹤0.01% | 7677 |
|
|
2018
Q4 | – | Sell |
-450
| Closed | -$102K | – | 9184 |
|
|
2018
Q3 | $102K | Buy |
+450
| New | +$72.8K | ﹤0.01% | 8572 |
|
|
2018
Q2 | – | Sell |
-483
| Closed | -$88K | – | 8868 |
|
|
2018
Q1 | $88K | Buy |
+483
| New | +$108K | ﹤0.01% | 7750 |
|
|
2017
Q4 | – | Sell |
-510
| Closed | -$109K | – | 8010 |
|
|
2017
Q3 | $109K | Sell |
510
-333
| -40% | -$65.1K | ﹤0.01% | 7005 |
|
|
2017
Q2 | $159K | Sell |
843
-1,127
| -57% | -$221K | ﹤0.01% | 6701 |
|
|
2017
Q1 | $488K | Buy |
+1,970
| New | +$484K | ﹤0.01% | 5059 |
|
Other funds holding CRBP
CAM
O
VCM
PM
DP
SCM
AC
Citadel Advisors's CRBP Position: Q1 2026 in Review
Citadel Advisors reduced its Corbus Pharmaceuticals (CRBP) stake by 14% in Q1 2026, selling an estimated $978K and leaving 727,060 shares worth $6.83M. The position accounts for ﹤0.01% of the portfolio, ranked #3848.
Citadel Advisors first reported a position in CRBP in Q4 2015 and has held it in 26 quarters since. The position peaked at $15.1M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.
- Citadel Advisors held 727,060 shares of Corbus Pharmaceuticals worth $6.83M as of Q1 2026.
- Citadel Advisors sold 116,133 Corbus Pharmaceuticals shares in Q1 2026, an estimated $978K.
- Corbus Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3848 holding.
- Citadel Advisors first reported a position in Corbus Pharmaceuticals in Q4 2015 and has held it in 26 quarters since.
- Citadel Advisors's Corbus Pharmaceuticals position peaked at $15.1M in Q2 2024.
- 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.